cholic acid ; potassium-salt | 5593-79-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholic acid ; potassium-salt
• 英文别名: Cholsaeure; Kalium-Salz；potassium;(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
• CAS: 5593-79-3
• 化学式: C₂₄H₃₉O₅*K
• 分子量: 446.669
• InChiKey: DULMETKZXZZUIU-TUJRSCDTSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.88
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  cholic acid ; potassium-salt 、 adenosine 5'-triphosphate disodium salt 在 苯甲基磺酰氟 、 potassium chloride 、 magnesium chloride 作用下， 以 水 、 三羟甲基氨基甲烷盐酸盐 为溶剂， 反应 0.5h， 以44.7 pmol/min/mg protein的产率得到cholyl-adenylate
  参考文献：
  名称：

  Chemical synthesis of bile acid acyl-adenylates and formation by a rat liver microsomal fraction

  摘要：

  In mammals, unconjugated bile acids formed in the intestine by bacterial deconjugation are reconjugated (N-acylamidated) with taurine or glycine during hepatocyte transport. Activation of the carboxyl group of bile acids to form acyl-adenylates is a likely key intermediate step in bile acid N-acylamidation. To gain more insight into the process of bile acid adenylate formation, we first synthesized the adenylates of five common, natural bile acids (cholic, deoxycholic, chenodeoxycholic, ursodeoxycholic, and lithocholic acid), and confirmed their structure by proton NMR. We then investigated adenylate formation by subcellular fractions of rat liver (microsomes, mitochondria, cytsol) using a newly developed LC method for quantifying adenylate formation. The highest activity was observed in the microsomal fraction. The reaction required Mg2+ and its optimum pH was about pH 7.0. In term of maximum velocity (V x) and the Michaelis constant (K), the catalytic efficiency of the enzyme under the conditions used was highest with cholic acid of the bile acids tested. The formation of cholyl-adenylate was strongly inhibited by lithocholic and deoxycholic acid, as well as by palmitic acid; ibuprofen and valproic acid were weak inhibitors. In cholestatic disease, such adenylate formation might lead to subsequent bile acid conjugation with glutathione or proteins. (C) 2009 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2009.04.003
• 作为试剂：
  描述：

  丁二酸单甲酯 、 胆酸 在 甲醇 、 cholic acid ; potassium-salt 、 potassium carbonate 作用下， 生成 27-nor-3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid
  参考文献：
  名称：

  Iterative Probability Kinematics

  摘要：

  Following the pioneer work of Bruno De Finetti [12], conditional probability spaces (allowing for conditioning with events of measure zero) have been studied since (at least) the 1950's. Perhaps the most salient axiomatizations are Karl Popper's in [31], and Alfred Renyi's in [33]. Nonstandard probability space [34] are a well known alternative to this approach. Vann McGee proposed in [30] a result relating both approaches by showing that the standard values of infinitesimal probability functions are representable as Popper functions, and that every Popper function is representable in terms of the standard real values of some infinitesimal measure. Our main goal in this article is to study the constraints on (qualitative and probabilistic) change imposed by an extended version of McGee's result. We focus on an extension capable of allowing for iterated changes of view. Such extension, we argue, seems to be needed in almost all considered applications. Since most of the available axiomatizations stipulated (definitionally) important constraints on iterated change, we propose a non-question-begging framework, Iterative Probability Systems (IPS) and we show that every Popper function can be regarded as a Bayesian IPS. A generalized version of McGee's result is then proved and several of its consequences considered. In particular we note that our proof requires the imposition of Cumulativity, i.e. the principle that a proposition that is accepted at any stage of an iterative process of acceptance will continue to be accepted at any later stage. The plausibility and range of applicability of Cumulativity is then studied. In particular we appeal to a method for defining belief from conditional probability (first proposed in [42] and then slightly modified in [6] and [3]) in order to characterize the notion of qualitative change induced by Cumulative models of probability kinematics. The resulting cumulative notion is then compared with existing axiomatizations of belief change and probabilistic supposition. We also consider applications in the probabilistic accounts of conditionals [1] and [30].

  DOI：

  10.1023/a:1012277218013

文献信息

• [EN] STABLE INDOLE-3-PROPIONATE SALTS OF S-ADENOSYL-L-METHIONINE<br/>[FR] SELS D'INDOLE-3-PROPIONATE STABLES DE LA S-ADÉNOSYL-L-MÉTHIONINE
  申请人：HEBERT SAM E LLC

  公开号：WO2014113609A1

  公开（公告）日：2014-07-24

  Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indole-3-propionic acid salts and processes for making same.

  本发明公开了稳定的S-腺苷甲硫氨酸的吲哚-3-丙酸盐，或其药用可接受的盐，以及包含吲哚-3-丙酸盐的药物组合物，使用吲哚-3-丙酸盐的方法和制备方法。
• METHOD FOR QUANTIFICATION OF SOLUBLE LR11
  申请人：Sekisui Medical Co., Ltd.

  公开号：EP2256497A1

  公开（公告）日：2010-12-01

  Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.

  本发明提供了一种通过免疫学方法方便准确地定量检测血清等生物样品中可溶性 LR11 的方法，无需进行任何复杂的分离操作。一种对来自哺乳动物的样品中的可溶性 LR11 进行免疫定量的方法，包括用至少一种表面活性剂处理样品的步骤，该表面活性剂选自由聚氧亚烷基醚、聚氧亚烷基苯基醚、烷基糖苷、烷硫基糖苷、酰基-N-甲基葡萄糖酰胺和胆酸盐组成的组。
• Methods and related compositions for reduction of fat and skin tightening
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10058561B2

  公开（公告）日：2018-08-28

  Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

  本发明公开了使用药理活性洗涤剂减少局部脂肪沉积和收紧松弛皮肤的组合物和方法。药理活性洗涤剂组合物还可包括消炎剂、镇痛剂、分散剂或抗分散剂以及药学上可接受的赋形剂。药理活性洗涤剂组合物适用于治疗局部脂肪堆积，例如下眼睑脂肪疝出、脂肪营养不良和与橘皮组织有关的脂肪沉积，而且不需要进行抽脂等外科手术。
• Double metal cyanide catalysts for preparing polyether polyols
  申请人：——

  公开号：US20020198099A1

  公开（公告）日：2002-12-26

  The invention is directed to a double-metal cyanide catalyst for the preparation of a polyether polyol by the polyaddition of an alkylene oxideon to a starter compound containing active hydrogen atoms, wherein the DMC catalyst comprises a) at least one double-metal cyanide compound; b) at least one organic complexing ligand; and c) two different complexing components.

  本发明涉及一种氰化双金属催化剂，用于将环氧亚烷基与含有活泼氢原子的起始化合物进行加成反应制备聚醚多元醇，其中 DMC 催化剂包括 a) 至少一种氰化双金属化合物；b) 至少一种有机络合配体；以及 c) 两种不同的络合组分。
• Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
  申请人：Bayer Corporation

  公开号：EP0523406B1

  公开（公告）日：1998-12-09